Clinical Proteomics of Breast Cancer

Y.      Baskin; T.      Yigitbasi

doi:10.2174/138920210793175930

Abstract

Despite the lifetimes that increased in breast cancers due to the the early screening programs and new therapeutic strategies, many cases still are being lost due to the metastatic relapses. For this reason, new approaches such as the proteomic techniques have currently become the prime objectives of breast cancer researches. Various omic-based techniques have been applied with increasing success to the molecular characterisation of breast tumours, which have resulted in a more detailed classification scheme and have produced clinical diagnostic tests that have been applied to both the prognosis and the prediction of outcome to the treatment. Implementation of the proteomics-based techniques is also seen as crucial if we are to develop a systems biology approach in the discovery of biomarkers of the early diagnosis, prognosis and prediction of the outcome of the breast cancer therapies. In this review, we discuss the studies that have been conducted thus far, for the discovery of diagnostic, prognostic and predictive biomarkers, and evaluate the potential of the discriminating proteins identified in this research for clinical use as breast cancer biomarkers.

Keywords: Breast cancer, early diagnosis, prognostic markers, proteomic techniques, micro array techniques, mass spectrometry, surface enhanced laser desorption ionisation, matrix-assisted laser desorption ionisation, cancer, diagnosis, markers, array techniques, spectrome-try, enhanced, matrix-assisted, biomarkers, cell proliferation, genom, proteome, 2DE, FFE, IPG, DIGE, IEF, ICAT, MudPIT, MALDI, ESI, SELDI, TOF, BRCA2, CCND1, BRCA1, ERBB2, EGFR, ITIH4, TNM classification, ASCO, NAF, TIF, HUPO